Free Shipping On Orders Over $1,000!

MPP5/PALS1 Polyclonal Antibody

Applications

  • WB
  • ELISA
  • IHC-P
  • IHC-F
  • IF(IHC-P)
  • IF(IHC-F)
  • IF(ICC)
  • ICC

Predicted Reactivity

  • Human
  • Mouse
  • Rat
  • Dog
  • Cow
  • Sheep
  • Pig
  • Horse
  • Chicken
  • Rabbit
Overview
Catalog # bs-11887R
Product Name MPP5/PALS1 Polyclonal Antibody
Applications WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC), ICC
Predicted Reactivity Human, Mouse, Rat, Dog, Cow, Sheep, Pig, Horse, Chicken, Rabbit
Specifications
Conjugation Unconjugated
Host Rabbit
Source KLH conjugated synthetic peptide derived from human MPP5/PALS1
Immunogen Range 201-300/675
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
Target
Subcellular location Cytoplasm, Cell membrane
Synonyms FLJ12615; MAGUK p55 subfamily member 5; Membrane protein palmitoylated 5; MPP 5; MPP5; MPP5_HUMAN; PALS 1; PALS1; Protein associated with Lin-7; Stardust Drosophila; Stardust.
Background Two highly conserved complexes are responsible for the assembly of tight junctions, the Crumbs-Pals1-Patj complex and the Cdc42-Par6-Par3-aPKC complex. Tight junctions assist in the formation of polarity in the epithelia by establishing a barrier to separate apical and basolateral membranes. Pals1, importantly, mediates interaction between the two complexes via interaction with Par6. Loss of Pals1 function results in delayed polarization, decreased transepithelial electrical resistance and an inability to form lumenal cysts. Because tumors exhibit perturbations in epithelial polarity, Pals1 presents a new potential target in the study of carcinogenesis.
Application Dilution
WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200
ICC 1:100-500